Passage BIO, Inc. (PASG) · Nov 19, 2026 · Other events
Above the bar — 57% ORR at 24 mg; responses ongoing up to 19 months
Passage Bio’s clinical update highlights a 57% REM-422 response rate at the recommended Phase 2 dose, with responses lasting up to 19 months.
Passage Bio is being repositioned around Remix’s oncology pipeline. The company has wound down its gene-therapy programs and is moving toward completing its merger with Remix, whose lead asset is REM-422; Passage shareholders are expected to own only about 6% of the combined company, making this clinical program the substance of the new business story.
The update strengthens an already-positive clinical signal rather than creating one from scratch. Earlier public data had already shown activity in biomarker-positive ACC, but this filing raises the response rate at the recommended 24 mg dose to 57% and extends the observed response durability to 19 months. The sample remains very small—just 7 efficacy-evaluable biomarker-positive patients at the recommended dose—so the result is encouraging, not yet definitive.
| Metric | Current data | Comparison |
|---|---|---|
| ORR at 24 mg (Key findings) | 57% | 4 of 7 patients |
| Partial responses, all doses (Key findings) | 10 | 32 BM+ patients |
| Duration of response (Key findings) | Up to 19 months | Median not reached |
| Time on treatment (Key findings) | Up to 27 months | Ongoing |
| Median PFS, BM+ patients (Key findings) | Not reached | BM−: 9 months |
| Phase 1 enrollment (Study update) | 69 patients | 60 efficacy-evaluable |
The most important change is durability and patient selection. Median response duration and median progression-free survival have not yet been reached in biomarker-positive patients, while no objective responses were observed in biomarker-negative patients across tested doses. That sharp biomarker split supports a narrower but more credible precision-medicine story: REM-422 may work best in a defined MYB-positive population, rather than broadly across ACC. 〔0〕 〔1〕
The evidence still carries early-stage limitations. This is an open-label, non-randomized Phase 1/2 study, and one of the four responses at 24 mg was unconfirmed. The filing also says the potentially registrational Phase 2 study is expected to complete enrollment by year-end, so the next test is whether the signal holds in a larger, biomarker-selected cohort. 〔2〕
Bottom line: This is a meaningful upgrade to Remix’s lead-asset story, mainly because response durability is improving alongside a strong biomarker-defined response rate. It advances the combined company’s clinical narrative, but the small, early dataset keeps it a promising signal rather than a validated efficacy readout.
Phase 2 enrollment completion, expected by year-end
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!